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Abstract
Background: Combined treatment of oncolytic adenoviruses with chemotherapeutic agents is foreseen as a
therapeutic option for cancer. Here we have investigated the potential to use gemcitabine in combination with the
oncolytic adenovirus AduPARE1A to treat pancreatic cancer and evaluate the underlying mechanism.
Methods: We treated pancreatic cancer cell lines BxPC-3 and PANC-1 with AduPARE1A and gemcitabine
individually or in combination and analyzed cell viability, combination index, apoptosis and viral production.
We also investigated the effects of the combination on tumor growth and mice survival in two xenograft
models. Furthermore, we analyzed uPAR promoter activity from different uPAR-controlled adenovirus and
studied NF-κB mediated effects.
Results: Synergistic cell killing from the combination AduPARE1A/Gemcitabine was observed in BxPC-3 and
PANC-1 cells. Moreover, the combination treatment produced therapeutic benefits over either individual modality in
two mouse models bearing orthotopic tumors, showing reduced tumor progression and significant prolonged mouse
survival. Mechanistic studies showed that the synergistic cell death was not due to an increase in viral replication but
occurred through an enhancement of apoptotic cell death. Gemcitabine stimulation increased the transcription of
uPAR-controlled transgenes through the induction of NF-κB acting on the uPAR promoter. Interestingly, NF-κB
gemcitabine-mediated induction of AduPAR adenoviruses interfered with the activation of NF-κB regulated
genes, probably as a result of an intracellular competition for NF-κB DNA binding. Consequently, AduPARE1A
infection sensitized cells to gemcitabine-induced apoptosis in the combined treatment.
Conclusions: These data highlights the potential of the combination as a treatment modality for pancreatic
cancer patients.
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Background
Pancreatic cancer is a particularly devastating disease,
ranked as the fourth leading cause of cancer-related death
and a 5-year survival rate of only 6 % [1].
Replication-selective oncolytic adenoviruses are designed
to replicate and spread into the tumor, resulting in cancer
cell lysis. Oncolytic mutants are being evaluated in the
clinic and emerge as a novel approach to treat cancer.
Clinical trials in pancreatic cancer patients with ONYX-
015, a p53 binding defective oncolytic adenovirus, proved
that the administration was safe, although clinical efficacy
was not observed when administered alone and only
minor responses and stable disease were observed in com-
bination with gemcitabine [2].
We previously developed an oncolytic adenovirus that
drives the E1A gene under the control of the urokinase-
type plasminogen activator receptor (uPAR) promoter,
designated AduPARE1A, and showed its selective replica-
tion and its strong antitumor activity in pancreatic cancer
models [3, 4]. Despite its anticancer activity demonstrated
in the preclinical studies as a monotherapy, multimodal
strategies to enhance antitumor efficacy are essential for
successful clinical outcome.
Gemcitabine has been the standard chemotherapy treat-
ment in patients with pancreatic cancer since 1997 with
modest improvements in median overall survival [5]. More
recently, a 2-months increase in overall survival has been
observed in the combination treatment of gemcitabine
and nab-paclitaxel [6]. Thus most likely patients that will
enter clinical trials with oncolytic viruses are expected to
be receiving gemcitabine. Combination treatment of onco-
lytic mutants and gemcitabine has already been explored
for given viruses and improved anticancer effects have
been reported [7–10]. However, the mechanism of action
supporting the benefits of the combination have been
quite different in line with the individual characteristics
that every oncolytic adenovirus possesses. In fact, a major
concern on the combination therapy is that the combin-
ation may impede the therapeutic function of each other.
In the current work we have examined the effects of the
combination treatment AduPARE1A and gemcitabine, in
pancreatic cancer in vitro and in vivo. We have observed a
synergistic anticancer effect in vitro and a significant po-
tentiation of tumor growth suppression in xenograft
models. Mechanistic studies identified a NF-κB uPAR pro-
moter activation mediated by gemcitabine induction. As a
consequence there was increased sensitization to gemcita-
bine-induced apoptosis in the combined treatment.
Results
Combination therapy of gemcitabine and AduPARE1A
show synergistic effects
To investigate the potential interest of gemcitabine and
AduPARE1A combination therapy for pancreatic cancer,
we first examined the cytotoxic effects of individual treat-
ments and their combination in BxPC-3 and PANC-1 cell
lines. Cells were infected with different viral doses of Adu-
PARE1A and exposed to several gemcitabine concentra-
tions, alone or in combination, and cell viability of the
culture was measured 3 days later. MTT assays showed a
dose–response effect in all cases. Combination treatment
significantly reduced the IC50 of each agent, in both
BxPC-3 and PANC-1 cells (Fig. 1a).
Pharmacological interaction between the above-mentioned
treatments was assessed by Combination Index analysis
(CI) in both PANC-1 and BxPC-3 cells. CI was calculated
for 20–80 % fractional inhibition. In Bx-PC-3, at all the
fractions analyzed, the CI was lower than one, indicating a
potentiation effect of AduPARE1A when combined with
gemcitabine, and vice versa, highlighting that both treat-
ments were synergistic. In PANC-1 cells synergism started
to show at 40 % of the inhibitory fraction (Fig. 1b).
In vivo multimodal gemcitabine and AduPARE1A therapy
significantly improved mouse survival over either
individual therapy in animals bearing orthotopic BxPC-3
and PANC-1 tumors
To analyze the impact of the combined treatment in vivo,
BxPC-3-Luc and PANC-1-Luc mice bearing orthotopic tu-
mors were treated with intravenous injection of a single
dose of AduPARE1A 5 × 1010 (vp/mouse), 3 weekly doses
of gemcitabine (160 mg/Kg) or a combination treatment
based on a weekly dose of gemcitabine and a single Adu-
PARE1A dose, following the protocol indicated in Fig. 2a.
All treatments significantly reduced tumor progression,
except for gemcitabine treatment in PANC-1 xenografts,
as indicated by bioluminescence quantification analysis
(Fig. 2b). Mouse survival was significantly prolonged in the
combined treatment with respect to gemcitabine or Adu-
PARE1A monotherapy (Fig. 2c). The median survival in
mice bearing BxPC-3 Luc tumors was of 22 days for the
saline group and of 57 days for the combined treatment.
The median survival in mice bearing PANC-1-Luc tumors
was of 37 days for the saline treated group and of 79.5 days
for the combined treatment. The enhanced anticancer ef-
fects correlated with increased cleaved active caspase-3
immunostaining in the combined treatment, suggesting
enhanced apoptosis (Additional file 1: Figure S1).
AduPARE1A and gemcitabine combined treatment
decrease viral replication but increase apoptotic cell
death
To understand the cell death mechanisms mediating the
effects of the combined treatment, we analyzed whether
gemcitabine-induced effects on viral replication could be
involved in the increase of cell killing. BxPC-3 and
PANC-1 cells were transduced with 4.000 vp/cel or
200 vp/cel of AduPARE1A and treated with 50 ng/ml or
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500 μg/ml of gemcitabine respectively. Viral replication
was assessed at 4 h after transduction, corresponding to
the viral input dose, and at 72 h. In the absence of gem-
citabine significant viral replication could be observed in
both cell types. However, the presence of gemcitabine
slightly impaired adenovirus replication in BxPC-3 cells,
and completely blocked it in PANC-1 cells (Fig. 3a).
These results exclude the increase of viral replication as
a mechanism to enhance cell death in the context of
combined treatment. Next, we evaluated the effects of
the combined treatment on apoptotic cell death. BxPC-3
and PANC-1 cells were exposed to AduPARE1A and
gemcitabine, either alone or in combination. The same
viral doses indicated above and gemcitabine concentra-
tions of 50 ng/ml in BxPC-3 or 500 μg/ml in PANC-1
cells were used. Apoptotic cell death was measured 48 h
Fig. 1 Evaluation of the cytotoxic effects of the combination AduPARE1A plus gemcitabine in cellular models. a Dose–response curves of
gemcitabine, AduPARE1A or combined treatment in BxPC-3 and PANC-1 cell lines. Cells were seeded in triplicate in a 96-well plate (3 × 103 cells/
well) and treated with a dose range of gemcitabine (ng/mL) and/or AduPARE1A (vp/mL). Cell viability was measured 3 days later, and is expressed
as the percentage of absorbance of treated cells compared with mock-treated cultures. IC50 values for monotherapy or combination therapy for
each treatment are represented in bar graphs. b Combination Index values (CI) for the interaction of gemcitabine and AduPARE1A treatments are
depicted as a function of inhibitory fractions. Results are expressed as a mean of at least four independent experiments ± SEM
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later by the expression of activated caspase-3 and cleaved
PARP. Western blot analysis shows that, in both cell lines,
the expression of activated caspase-3 was significantly in-
creased in the combination treatment when compared to
gemcitabine alone. Cleaved PARP was also significantly in-
creased in the combination treatment. No apoptotic effect
was observed with the virus alone (Fig. 3b, c). These
results suggest that AduPARE1A sensitizes pancreatic
cancer cells to gemcitabine-induced apoptosis.
Gemcitabine induces the activity of uPAR-controlled
adenoviruses
To investigate the mechanism involved in the synergistic
anti-cancer effects of AduPARE1A and gemcitabine we
Fig. 2 Antitumoral activity of combined AduPARE1A plus gemcitabine treatment in BxPC-3-Luc and PANC-1-Luc orthotopic tumors. a Schematic
representation of treatment protocols applied in mice bearing BxPC-3 and PANC-1 orthotopic tumors. BxPC-3-Luc and PANC-1-Luc orthotopic tumors
were treated with a weekly dose of 160 mg/kg of gemcitabine for 3 weeks (T1), with a single dose of AduPARE1A (5 × 1010 vp) (T2), with the combined
treatment, replacing a dose of gemcitabine for the AduPARE1A (T3), or with saline in the control group. b Luciferase quantification of bioluminescent
emission images from BxPC-3-Luc and PANC-1-Luc tumor-bearing mice, at different time points. Bars graph represent luciferase quantification at 21
and 35 days after treatment in BxPC-3 and PANC-1, respectively. Results are expressed as photons per second. Values are represented as mean ± SEM).
(*p < 0.05; **p > 0.01; ***p < 0.001). c Kaplan-Meier survival curves in BxPC-3-Luc tumors: (T1: log rank test = 0.003, T2: log rank test = 0.001, T3: log rank
test = 0.0001); in PANC-1-Luc tumors (T1: log rank test = 0.014, T2: log rank test = 0.0002, T3: log rank test = 0.0006). BxPC-3-Luc xenografts: saline: n = 8;
Gem: n = 9; AduPARE1A n = 6; combined: n = 8. PANC-1-Luc xenografts: saline: n = 7; Gem: n = 6; AduPARE1A n = 7; combined n = 6
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Fig. 3 Analysis of the effects of combined treatments on AduPARE1A production and the level of apoptotic cell death in BxPC-3 and PANC-1 cell lines.
a AduPARE1A viral production in BxPC-3 and PANC-1 cell lines at 72 h after infection. Cell lines were infected with AduPARE1A (4000 vp/cell; 200 vp/
cell, BxPC-3 and PANC-1 respectively) and 4 h later the medium was removed and treated, or not, with Gemcitabine (50 ng/ml; 500 μg/ml, BxPC-3 and
PANC-1 respectively) for 72 h. Viral DNA obtained from whole cell extracts at 4 and 72 h was analyzed for hexon amplification by qPCR. Values are
represented as a mean ± SEM of four independent experiments (*P < 0.05). b and c Western blot of cleaved caspase-3 (b) and cleaved PARP (c) in
BxPC-3 and PANC-1 cell lines treated with mock, gemcitabine (50 ng/mL; 500 μg/mL, BxPC-3 and PANC-1 respectively), AduPARE1A (4000 vp/cell;
200 vp/cell, BxPC-3 and PANC-1 respectively) or AduPARE1A plus gemcitabine at 48 h after treatment. Bar graphs show quantification of cleaved
caspase-3 and cleaved PARP related to GAPDH expression in n = 5 (BxPC-3) and n = 6 (PANC-1) independent experiments. (*P < 0.05, **P < 0.01)
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first evaluated the expression of the E1A viral gene in
BxPC-3 and PANC-1 cultures infected with AduPARE1A
in the presence or absence of gemcitabine. We observed a
significant increase in the E1A mRNA transcript in the
presence of gemcitabine in the two cells lines analyzed
(Fig. 4a). E1A induction in gene expression by gemcitabine
was observed at escalating viral doses (Fig. 4b).
To evaluate whether the increase in E1A expression
was the consequence of uPAR promoter activation medi-
ated by gemcitabine stimuli, we decide to analyze the ef-
fects of gemcitabine on the expression of different
transgenes also controlled by the uPAR promoter.
BxcPC-3, PANC-1 and MIAPaCa-2 cells were trans-
duced with AduPARTKT, a non-replicative adenovirus
that expresses a modified form of the Herpes simplex
thymidine kinase gene under the control of the uPAR
promoter, in the presence or not of gemcitabine. Ana-
lysis of TK expression revealed increased levels of TK
mRNA in the presence of gemcitabine (Fig. 4c). Cell
transduction with AduPARLuc, a reporter adenovirus
that contains the luciferase expression regulated by the
uPAR promoter, showed that luciferase activity was
significantly higher in cells that received AduPARLuc
and gemcitabine (Fig. 4d). Furthermore, gemcitabine
treatment also induced endogenous uPAR mRNA over-
expression (Fig. 4e).
These findings indicate that gemcitabine enhances
uPAR promoter transcriptional activity.
NF-κB activation mediates gemcitabine uPAR-induction
Next we asked how gemcitabine could mediate the activa-
tion of uPAR-controlled transgenes. Gemcitabine treat-
ment has been shown to induce NF-κB activation in small
cell lung cancer and pancreatic cancer cells [11, 12]. The
proximal uPAR promoter fragment of 400 bp, used in the
uPAR-adenoviruses, contains an NF-κB-like site at pos-
ition −45 that specifically binds the transcription factor
NF-κB, upregulating the uPAR gene [13]. To study the in-
volvement of NF-κB mediating uPAR activation by gemci-
tabine in AduPAR-regulated viruses, PANC-1 and BxPC-3
cells were transduced with AduPARLuc and treated or not
with gemcitabine for 24 h in the presence or absence of
BAY 11-7082 (BAY), an inhibitor of κB kinase (IKK). As
shown in Fig. 5a, uPAR promoter activity was induced by
gemcitabine, and such induction was strongly suppressed
by the BAY inhibitor in both PANC-1 and BxPC-3 cells.
The gemcitabine stimuli triggering NF-κB activation
was also evident in the NF-κB reporter transfection
Fig. 4 Evaluation of the effects of gemcitabine on the transcriptional activation of the uPAR promoter. a Analysis of E1A gene expression in BxPC-3 and
PANC-1 cells infected with AduPARE1A and treated with gemcitabine (20 ng/ml and 250 μg/ml) for 24 h. b Analysis of E1A gene expression in BxPC-3
cells infected with increasing viral doses in the presence or absence of 10 ng/ml of gemcitabine. c Analysis of TK gene expression in BxPC-3, PANC-1
and MIAPaCa-2 cell lines transduced with AduPARTKT (18.790 vp/cell, 1466 vp/cell and 11716 vp/cell, respectively) and treated with gemcitabine
(20 ng/ml, 250 μg/ml and 20 ng/ml respectively) for 24 h. d Luciferase activity in BxPC-3, PANC-1 and MIAPaCa-2 cell lines transduced with 10 MOI
(BxPC-3, PANC-1) or 20 MOI (MIAPaCa-2) of AduPARLUC and treated or not with gemcitabine (20 ng/ml, 250 μg/ml and 20 ng/ml respectively) for
24 h. Results are expressed as RLU (LU/μg of protein). e Expression of endogenous uPAR gene in BxPC-3, PANC-1 and MIAPaCa-2 cell lines treated with
gemcitabine (20 ng/ml, 250 μg/ml and 20 ng/ml respectively) for 24 h. Results are represented as the mean ± SEM of at least three
independent experiments
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experiments (Fig. 5b). To further demonstrate the
involvement of NF-κB mediating gemcitabine-induced
uPAR activation, cells were transfected with puPARLuc or
a plasmid with NF-κB mutagenized sites in the uPAR
promoter, the puPARLuc-NF-κB mut. The mutation of
the NF-κB binding site in the uPAR promoter abrogated
the gemcitabine induced uPAR activation observed in
puPARLuc transfected cultures (Fig. 5c). The above results
strongly support the involvement of NF-κB in the
gemcitabine-mediated uPAR activation. However, NF-κB
is thought to play an antiapoptotic role and NF-κB signal-
ing pathways are often regarded as mediators of chemore-
sistance [14]. Next we aimed to understand how the
increase uPAR promoter activation by NF-κB- gemcita-
bine induction could mediate the synergistic cell killing
effect in the AduPARE1A and gemcitabine combined
treatment. To this end, cells were transduced with in-
creasing doses of AduPARE1A in the presence or not of
gemcitabine and transfected with the 3xκB-Luc reporter
plasmid. Increased concentration of viral particles strongly
suppressed the gemcitabine induction of the NF-κB re-
sponsive plasmid, while E1A was transcriptionally acti-
vated (Fig. 5d, Additional file 2: Figure S2). Similar results
were observed with the AduPARTKT (Fig. 5d), suggesting
that the effect was independent of E1A, and probably the
large amount of viral particles in the cells exerted a decoy
effect of NF-κB, interfering with its natural binding to
endogenous NF-κB responsive genes. Interestingly, gemci-
tabine induction of the NF-κB responsive plasmid was su-
perior in cells expressing E1A from a uPAR promoter
with NF-κB mutagenized sites (puPARE1A- NF-κBmut)
than from its wild-type form, suggesting that in a context
in which NF-κB can not bind to the uPAR promoter there
is no decoy effect and NF-κB-response genes could be ac-
tivated (Fig. 5e). These data further supports an E1A-
independent effect since E1A will be poorly expressed in
the gemcitabine treated puPARE1A-NF-κBmut cultures,
because this mutation abrogates gemcitabine activation of
the promoter as shown in Fig. 5c.
Collectively, these results suggest that higher amounts
of AduPARE1A viral particles will interfere with NF-κB
activation, facilitating gemcitabine-induced apoptosis,
leading to in vitro synergistic cell death and improve an-
titumor response of the combination treatment.
Discussion
Oncolytic adenoviruses are now under evaluation in
clinical trials in patients with pancreatic cancer [15–17].
These agents are attractive treatment options either
alone or in combination with traditional cytotoxic drugs.
Previous work from our group has shown the antitumor
efficacy and tumor selectivity of AduPARE1A [3, 4]. The
current study aimed to determine the efficacy to com-
bine AduPARE1A and gemcitabine commonly used to
treat pancreatic cancer. We found a synergistic cell kill-
ing effect in the combination treatment. In vivo, in two
orthotopic xenograft models, combined treatment pro-
longed mouse survival compared to either therapy alone
providing evidence of the efficacy of AduPARE1A plus
gemcitabine for pancreatic cancer. Furthermore, we pro-
vide evidences on the mechanisms of such synergistic
interaction.
The increased cell death in the combined treatment
was not due to an improvement in viral replication, on
the contrary, replication was attenuated by the presence
of gemcitabine. The effect was more pronounced in
PANC-1 cells, where much higher doses of gemcitabine
were used. In fact, viral attenuation by DNA damaging
agents has also been observed in the E1B19K oncolytic
adenoviral mutants [8] and in replication-selective her-
pes mutants targeting pancreatic cancer cells [18]. The
G1/S cell-cycle block triggered by gemcitabine limits
DNA cellular synthesis, hampering to support viral propa-
gation [8].
Interestingly, the increased cell death in the combination
treatment could be explained by an enhancement of
gemcitabine-induced apoptosis since we observed an aug-
mented activity of caspase-3. Several authors have postu-
lated that increased E1A expression might be responsible
for most of the synergistic effects in combination treat-
ments of oncolytic adenovirus and DNA damaging agents,
since E1A is a potent apoptotic inducer [8, 10, 19, 20]. The
pro-apoptotic functions of E1A, have been linked to its
capacity to upregulate Egr-1 which is directly involved in
(See figure on previous page.)
Fig. 5 Gemcitabine promotes the activity of NFkB, leading to an increase in uPAR promoter activation. a Luciferase activity in BxPC-3 and PANC-1 cell
lines transduced with AduPARLuc, 10 or 20 MOI respectively, and treated with 5 μM of kinase inhibitor BAY 11-7082 (Calbiochem) for 1 h, and then ex-
posed to (20 ng/ml and 250 μg/ml) of gemcitabine for 24 h. Results are expressed as light units (LU) normalized to total protein levels (RLU). b Lucifer-
ase activity of 3xκB-Luc reporter plasmid in 293T cells treated with 200 ng/ml of gemcitabine for 24 h. Results are expressed as LU normalized to β-gal
activity. c Luciferase activity of puPARLuc and puPAR-NFκBmut reporter plasmid in 293T cells treated with 200 ng/ml gemcitabine for 24 h. Results are
expressed as LU normalized to β-gal activity. d Luciferase activity of 3xκB-Luc reporter plasmid in 293T cells transduced with increasing doses of Adu-
PARE1A (left panel) or AduPARTKT (right panel) and treated or not with 200 ng/ml gemcitabine. Results are expressed as fold-change of LU normalized
to total protein levels (RLU). Values represent the mean ± SEM of five independent experiments. e Luciferase activity of 3xκB-Luc reporter plasmid in
293T cells co-transfected with puPARE1A or puPARE1A-NF-κBmut, in the presence or absence of 200 ng/ml gemcitabine. Results are expressed as fold-
change of LU normalized to β-gal activity (RLU). Values represent the mean ± SEM of four independent experiments
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Bim transactivation. The alterations of Bim contribute to
Bax activation and subsequent caspase activation [21]. We
observed an increase in E1A expression upon gemcitabine
treatment, suggesting that at least part of the synergism
could rely on the pro-apoptotic functions of E1A. However
this seems unlikely since AduPARE1A oncolytic adeno-
virus retains all the viral functions and infected cells
also express the anti-apoptotic E1B and E3 viral proteins,
what may hamper or at least mitigate E1A activity. In fact,
AduPARE1A alone was not able to trigger caspase-3 acti-
vation. Thus, other mechanisms might be operating in the
AduPARE1A cooperation to gemcitabine-induced apop-
tosis. It should be considered that E1A has been shown to
induce mesenchymal-to epithelial conversion resulting in
the formation of gap junctions, what facilitates the cell-to
cell transfer of gemcitabine toxic metabolites and the
spread of gemcitabine cytotoxicity [22, 23].
We observed that the increase in E1A expression by
the combined treatment was the consequence of a tran-
scriptional activation of the uPAR promoter mediated by
gemcitabine. Induction of transgene expression was ex-
tended to all uPAR-promoter controlled adenoviral vec-
tors analyzed such as the AduPARTKT, increasing TK
transcriptional levels and the AduPARLuc, enhancing lu-
ciferase activity. Furthermore, gemcitabine induced tran-
scriptional activation of the endogenous uPAR gene.
These data highlight that gemcitabine induction of uPAR
adenoviruses enhances the biological effects of the con-
trolled transgenes. Such increase in transgene expression
could partially account by the gemcitabine enhancement
of viral infectivity, as reported by some authors [10, 24].
However, since we observed a gemcitabine-mediated in-
crease in the uPAR promoter transcriptional activity,
most likely the increased transgene expression will result
from the interaction of different transcription factors to
cis acting regulatory sequences in the uPAR gene [25].
One of the key factors regulating the uPAR promoter is
NF-κB [13]. NF-κB is constitutively active in pancreatic
cancer and gemcitabine is able to induce NF-κB bind-
ing activity. In this line, we observed that gemcitabine
induced-uPAR promoter activation was completely
blocked by the NF-κB inhibitor BAY11-7082, and gem-
citabine was unable to activate a uPAR promoter with
NF-κB mutagenized binding sites. However, activation
of NF-κB has been linked to reduced cytotoxicity and
antiapoptotic effects, and it is proposed as a mechanism
of gemcitabine resistance [26]. Interestingly, what we
observed is that in the combination treatment of Adu-
PARE1A and gemcitabine, at high viral doses, where
E1A is induced, AduPARE1A interferes with the activa-
tion of NF-κB regulated genes. E1A has been proposed
to counteract gemcitabine induced NF-κB activation
sensitizing cells to apoptosis [27], however in our stud-
ies the suppression of NF-κB activation would not only
account by E1A since the same kind of interference was
observed with AduPARTKT. These results support the
notion that there will be an intracellular competition
for NF-κB DNA binding, favoring AduPAR promoter
activation. As a consequence E1A will be highly
expressed. It could be speculated that in this scenario
endogenous NF-κB- responsive antiapoptotic genes
might be suppressed leading to reversal of gemcitabine
resistance and enhancement of apoptosis. The proposed
mechanism of synergistic activity between AduPARE1A
and gemcitabine is a novel mechanism that could also
extent to other viruses susceptible to NF-κB regulation.
Furthermore, the remarkable in vivo anti-cancer effects
could also result from the capacity of oncolytic adeno-
virus to disrupt tumor architecture thus facilitating
gemcitabine penetration [28].
Conclusions
In summary in the current study we show that the com-
bination of AuPARE1A and gemcitabine has a synergis-
tic cell killing effect that holds potential as a novel
therapy for pancreatic cancer treatment. We propose a
model of the operating mechanism underlying the syner-
gistic effects, through which gemcitabine will trigger an
NF-κB activation to induce uPAR promoter activity,
leading to an increase in E1A protein. The NF-κB tran-
scription factor binding to the high number of uPAR
sequences in the adenovirus will produce a sponge ef-
fect, interfering with NF-κB activation of antiapoptotic
genes, thus sensitizing gemcitabine-induced apoptosis.
Methods
Cell lines
Human pancreatic tumor cell lines: BxPC-3, PANC-1
and MIAPaCa-2, and 293T cells were obtained from the
American Type Culture Collection (ATCC; Rockville,
MD, USA). Luciferase-expressing cells PANC-1-Luc
and BxPC-3-Luc were established as previously de-
scribed [3, 29]. Cell lines were maintained in Dulbecco’s
modified Eagle’s medium (DMEM), supplemented with
10 % fetal bovine serum (FBS), penicillin (100 U/ ml),
streptomycin (100 μg/ ml), and glutamine (2 mM)
(GIBCO-Invitrogen). Every 2 months cells were plated
from a frozen vial of the original batch but were not au-
thenticated by the authors. Interspecies contamination
was tested by PCR routinely.
Chemicals and antibodies
Gemcitabine (Hospira UK Limited) was dissolved in
water to a concentration of 10 mg/ml. BAY 11-7082
(Calbiochem, La Jolla, CA) was dissolved in dimethyl
sulfoxide, stored at −20 °C, and protected from light.
The following antibodies were used in western blot
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analysis: Rabbit anti-Cleaved Caspase-3 (Asp175)
(Ref.9661, Cell Signaling Technology, MA, USA), Rabbit
anti-PARP (Cat. No.11835238001, Roche), Rabbit anti-
GAPDH (Ref.ABS16, Merck Millipore, Germany), HRP-
conjugated Goat anti-Rabbit (DakoCytomation,
Denmark).
Adenoviruses
Replication-defective adenoviruses AduPARLuc express
the firefly luciferase gene under the control of uPAR
promoter. This virus has already been described [3]. The
oncolytic AduPARE1A was constructed by inserting the
uPAR promoter (450-bp fragment) upstream the E1A
adenoviral gene [3]. AduPARTKT encodes a modified
Herpes Simplex virus thymidine kinase gene, as described
[30]. Experiments with AduPARE1A and AduPARTKT
were conducted with CsCl purified viral preparations and
results are expressed as vp/ml. AduPARLuc experiments
were performed with homogenates from viral infected
cells subjected to three rounds of freeze-thaw lysis and
viral doses are expressed as MOI.
Plasmid constructs
A 450-bp fragment of the uPAR promoter ( −402/+48
region) and the luciferase gene present in the pAd-
TrackuPARLuc [3] were excised and cloned into a
pGEM-T vector (puPARLuc). The reporter plasmid
puPARLuc-NF-κBmut was generated by directed muta-
genesis. The NF-kB binding site in the uPAR promoter
(located at −45 bp of transcription initiation site) 5'-GG
GAGGAGT-3' [13], was mutated to 5'-GGATCCAGT-3',
using the QuikChange Multi Site-Directed Mutagenesis
Kit (Agilent, CA USA), as recommended by the manu-
facturer and using the mutagenesis primer: 5'-ctctttcgc
aaaacgtctggatccagtccctggggccacaaaac-3'. puPARE1A was
generated by cloning the uPARE1A construct in a pGEM-
T vector. The NF-κBmutation in the puPARE1A to gen-
erate puPARE1A-NF-κBmut was carried out by directed
mutagenesis as described above. 3xκB-Luc reporter
plasmid was previously described [31].
Reporter gene assays
With Adenoviruses: Cells were transduced with Adu-
PARLuc, 4 h later virus was removed and replaced
with fresh medium containing or not BAY 11-7082
(Calbiochem) for 1 h and then exposed to gemcitabine
for 24 h. Luciferase activity was measured in a lumin-
ometer (Synergy HT, Biotek) with luciferin as a sub-
strate (Promega, Madison,USA). Results are expressed
as light units (LU) and normalized to total protein
levels.
With Reporter plasmids: 293T cells were seeded (40.000
cells/well) and co-transfected with luciferase reporter
plasmids (150 ng/well): 3xκB-Luc, puPARLuc or
puPARLuc-NF-κBmut or puPARE1A or puPARE1A-NF-
κBmut and the β-gal reporter plasmid (30 ng/well). Cal-
Phos mammalian transfection kit (Clontech, Takara Bio
Company Inc.) was used to transfection, following the
manufacturer guidelines. At 16 h post-transfection the
medium was change and new fresh medium or medium
containing 200 ng/ml of Gemcitabine was added. Twenty-
four hours later, cell lysates were analyzed for luciferase
activity using Luciferase Assay System (Promega), and β-
galactosidase activity was used as a control of transfection
efficiency.
Dose–response analysis and combination index analysis
BxPC-3 and PANC-1 cell lines were seeded in 96-well
plates at a density of 3 × 103 cells per well. Cells were
treated with different doses of gemcitabine (ng/mL), Adu-
PARE1A (vp/cell) or the combination of both treatments,
maintaining a constant ratio of gemcitabine:adenovirus of
1:800 or 1250:1 in BxPC-3 and PANC-1 respectively. Cell
viability was measured 3 days later, using the MTT colori-
metric assay (Ref.19265 USB, Affymetrix, CA USA). The
induction of synergism, summation or antagonism be-
tween gemcitabine and AduPARE1A treatments was ana-
lyzed by Combination Index analysis, by the adapted
method of Chou and Talay [32, 33]. Dose–response curves
were obtained for combined or single treatments by a
standard non-linear regression using GraphPad Prism
Software (CA, USA), and IC50 and combination index
values were calculated using Calcusyn Software (Biosoft,
Cambridge UK). CI >1 indicates synergism, CI = 1 additiv-
ity and CI <1 indicates antagonism between treatments.
Quantitative RT-PCR analysis of gene expression
Total RNA was extracted from different cells lines using
the RNeasy® Mini Kit (Qiagen). The cDNA was synthe-
sized from total RNA using a reverse transcriptase and
random hexamers (RETROscript® Kit, Ambion), accord-
ing to the manufacturer’s instructions. The PCR reac-
tions were performed in a total volume of 10 μl
containing SYBR Green I Master Mix (Roche) with
10 μM of each primer and 1 μl cDNA. Quantitative PCR
was performed in triplicate with the ViiA™ 7 System
(Applied Biosystems). Primers sequences for the differ-
ent genes are listed in Additional file 3: Table S1.
Western blot analysis
Cell lines were treated for 48 h with gemcitabine or/and
infected with AduPARE1A. After treatment, floating and
adherent cells were collected in lysis buffer (62.5 mM Tris
HCl pH6.8, 2 % Sodium Dodecyl Sulfate and 10 %
Glicerol) containing 1 % Complete Mini-Protease Inhibi-
tor Cocktail (Roche Diagnosis, Switzerland), and 5 mM
NaF. Cell lysates were boiled for 10 min at 98 °C. All
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protein extracts were quantified using BCA kit (Thermo
scientific, MA USA) and 80 μg of protein was resolved in
12 % SDS-PAGE and transferred to PVDF or nitrocellu-
lose membrane (Merk Millipore, Germany). Membranes
were immunobloted with anti-cleaved caspase-3 (1/200,
overnight at 4 °C) or anti-PARP (1/1000, 2 h at room
temperature) and anti GAPDH (1/3000, 1 h at room
temperature), rinsed with TBS-Tween and then incubated
with HRP-conjugated goat anti rabbit (1/2000, 1 h at
room temperature). Antibody labeling was detected by
Enhanced Chemoluminiscence Kit (Amersham, GE
Healthcare, Switzerland).
Viral genomes quantification
BxPC-3 and PANC-1 cells were infected with 4000 vp/
cell and 200 vp/cell, respectively. Culture medium was
removed at 4 h after infection and cells were treated, or
not with 50 ng/ml and 500 μg/ml of gemcitabine (in
BxPC-3 and PANC-1 respectively). Viral DNA was ob-
tained from cell and supernatant (lysed by three freeze
and thaw cycles) at 4 and 72 h after infection, using the
UltraClean BloodSpin DNA Isolation Kit (Mo Bio La-
boratories, CA USA) according to manufacturer’s in-
structions. Viral genomes were determined by Real Time
PCR using SYBR Green I Master mix (Roche Diagnos-
tics, Switzerland) and Hexon primers (described in Add-
itional file 3: Table S1). The adenovirus copy number
was interpolated in a standard curve, consisting of
adenoviral DNA dilutions in a background of genomic
DNA.
Bioluminescence assay and quantification
Animals were anesthetized with a mixture of isofluorane
and oxygen preparation and the substrate d-Firefly-
Luciferin (Xenogen, Alameda, CA) was administered i.p
(32 mg/kg). Luciferase activity was visualized and quan-
tified using an in vivo bioluminescent system (IVIS50;
Xenogen) and Living Image 2.20.1 Software overlay on
Igor Pro4.06A software (Wavematrics, Seattle, WA) was
used, as previously described [3]. Luciferase activity was
quantified from non-saturated images, measuring the
total amount of emitted light recorded by the CCD
camera.
Antitumoral efficacy
Male athymic nu/nu mice (6–8 weeks old, Harlan Iberica)
were used to generate human orthotopic pancreatic tu-
mors. Animal procedures met the guidelines of European
Community Directive 86/609/EEC and were approved by
the Local Ethical Committee.
Orthotopic human pancreatic cancer xenografts were
generated as previously described [29]. Briefly, 5 × 105
PANC-1-Luc and BxPC-3-Luc cells were injected into
the pancreas of 8-week-old male athymic nude mice, in
a final volume of 50 μl. When tumors reached 106–107
photons/s measured by in vivo bioluminescence, which
corresponds to approximately 100 mm3, animals were
randomly divided into four groups: Saline, GE, Adu-
PARE1A and AduPARE1A + GE, and were i.v injected
with AduPARE1A 5 × 1010 vp or PBS and or gemcita-
bine 160 mg/Kg or PBS following the protocol de-
scribed in Fig. 2a. Tumor growth was monitored by
bioluminescence analysis. Survival studies were per-
formed and animals were sacrificed according to ethical
guidelines.
Statistical analysis
Results are expressed as mean ± SEM of at least three
independent experiments. Statistical differences were de-
termined using Prism (version 5; GraphPad software)
and were considered significant for P values less than
0.05. Survival studies were performed to analyze time-to-
event probability using the SPSS software. The survival
curves (Kaplan–Meier curves) obtained were compared
for the different treatments. A log-rank test was used to
determine the statistical significance of the differences in
time-to-event. A p value of less than 0.05 was considered
statistically significant.
Additional files
Additional file 1: Figure S1. A) Schematic representation of treatment
protocols applied in mice bearing BxPC-3 subcutaneous tumors. B)
Representative images of IHC staining for Cleaved-Caspase3 (Ref.9661, Cell
Signaling Technology) in BxPC-3 tumors. Bar graph shows quantification of
cleaved-caspase3 cells per field. Results are represented as the mean ± SEM
of n ≥6 fields. (JPEG 110 kb)
Additional file 2: Figure S2. Expression of E1A gene in 293T cells
infected with AduPARE1A (1000 vp/cell) and treated, or not, with
gemcitabine (200 ng/ml). Results represented are the mean ± SEM of at
least four independent experiments. (DOCX 40 kb)
Additional file 3: Table S1. Primer sequences. (JPEG 1145 kb)
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